2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 10g

1,10-Diiododecane, 95.0%, 1g

3-Fluoro-5-hydroxybenzonitrile, 95.0%, 100g

3,5-PYRIDINEDICARBOXYLIC ACID, 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-, 3-METHYL 5-[(1-OXOBUTOXY)METHYL] ESTER, 97%, 25mg

N-ETHYLOXETAN-3-AMINE, 95.0%, 1g

Colonna capillare per GC ROTI®Cap-FFAP, 25 m, 0.53 mm, 1.00 µm, 1 Pezzo(i)

(4-Hydroxy-quinazolin-2-ylsulfanyl)-acetic acid, 95.0%, 2.5g

Bromoform (stabilized with 2-Methyl-2-butene) [for Spectrophotometry]>99.0%(GC)100mL

(S)-2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide hydrochloride, 95.0%, 25g

Afatinib Dimaleate, 98%, 200mg

4',5'-Dimethoxy-2'-methylacetophenone, 97.0%, 1g

1-(6-Methylpyridin-3-yl)-2-(4-(methylsulfinyl)phenyl)ethanone (Etoricoxib Impurity), 97%, 50mg

(S)-6-METHYL-2,3-DIHYDRO-1H-INDEN-1-AMINE HCL, 95.0%, 1g